Abstract

The last 35 years statistical data show that the conventional treatment results are not relevant to the patients’ survival rate improvement. The concept of standard oncology demonstrates a lot of disadvantages, which remarkably limit the therapeutic effectiveness. Recently a new approach appears to be more interesting: the so called “Personalized Treatment”. Hopefully, this is going to be the basics for achievement of better curable results. Molecular biology advancement has given the possibility of personalized treatment to be implemented. The use of chemo sensitivity tests gives the opportunity for anticancer drugs to be tested and each patient to be treated under personal combination. Another option for testing of anticancer drugs, food supplements and tumor sensitivity are Autonomic Muscular Tests (AMT). The American physician Dr. Omura [1] has elaborated and patented his own AMT (Bi-Digital O-ring Test-BDORT), which is used for diagnostics and treatment in cancer diseases. Since 2012 we have started to use chemo sensitivity test for circulating tumor cells (CTC) and modified version of Dr. Omura’s [1] AMT. This article reflects our initial experience in usage of personalized approach in the treatment of cancer patients.

Keywords: Personalized treatment; Cancer treatment; Circulating tumor cells; Chemo sensitivity test; Autonomic muscular test